INTRODUCTION {#s1}
============

Breast cancer is the most frequent malignant tumor among women worldwide. In 2012, there were an estimated \> 1.5 million new cases, slightly increasing in less developed regions, with incidence rates between 27 per 100,000 women in middle Africa and 92 per 100,000 women in northern America, ie, Canada and the United States.^[@B1],[@B2]^

In relation to mortality, breast cancer represents the most frequent cause of death among women in less developed regions and the second most frequent cause in most developed ones, with mortality rates between six (East Asia) and 20 deaths (western Africa) per 100,000 women.^[@B2]^

In the Americas, the situation among countries is variable. If the countries with the highest and lowest rates in the region are compared, Guatemala presents an incidence rate of 11.9 per 100,000 women and a mortality rate of 5 per 100,000 women, whereas the Bahamas presents a 98.9 per 100,000 women incidence rate and a 26.3 per 100,000 mortality rate in women. In North America, the country with the highest incidence and mortality rates in 2012 was the United States (92.9 and 14.9 per 100,000 women, respectively) and in South America, it was Uruguay (69.8 and 22.7 per 100,000 women, respectively). There is a clear difference in patients' survival among countries.^[@B2]^

Argentina has an incidence and mortality pattern similar to that of developed countries. It had an estimated incidence in 2012 of 71.2 per 100,000 women^[@B2]^ and a mortality rate in 2014 of 19.9 per 100,000 women. However, within the country, there are varied mortality patterns, with rates between 11.1 and 22.4 per 100,000 women (Jujuy and La Pampa provinces, respectively). It is important to mention that Jujuy is one of the provinces with the highest percentage of population with unsatisfied basic needs, whereas La Pampa is one of the provinces with a lower percentage of population with unsatisfied basic needs.^[@B3]^ Furthermore, according to breast cancer characteristics, it is common to find higher rates in developed areas.

Mortality trends in Argentina are declining. From 2000 to 2014, mortality trends in the country as a whole declined, with an estimated percentage of annual change of negative 2.1% in the last years of the period (data elaborated by the Cancer Epidemiological Surveillance and Report System of the National Cancer Institute on the basis of data from the Division of Health Statistics and Information of the Ministry of Health of Argentina).^[@B1]^ This trend is different if each province is considered: between 1997 and 2011, nine provinces presented declining trends, 11 had increasing trends, and there were four with almost no change.^[@B4]^

In 2010, the Cancer Epidemiologic Surveillance and Report System, part of the National Cancer Institute of the Ministry of Health, was established (SIVER-Ca--INC). One of the components of the system is the Institutional Cancer Registry of Argentina (RITA). This is a hospital-based registry developed on an online platform centralized at INC, with restricted access to users. It collects information on patients, tumors, diagnoses, and oncologic treatment processes. The information provided by this registry contributes to health services planning, improving oncology patient health care and follow-up, and comparing results. Furthermore, it is essential information for population-based cancer registries and future epidemiologic research, and it also contributes to rational management decisions for the diminution of inequities in cancer burden.

The aim of this article is to describe the sociodemographic, epidemiologic, and clinical characteristics of women with breast cancer registered in RITA between April 2012 and April 2016.

METHODS {#s2}
=======

This was an observational study analyzing cases with a diagnosis of breast cancer (C50\*) registered in RITA between April 2012 and April 2016.

The case definition in RITA includes any person of any sex, age, and place of residence diagnosed (in or out of institution) with malignant neoplasm; CNS neoplasm with uncertain or benign behavior; or neoplasm in situ of breast, cervix, bladder, or melanoma, who contacted the institution and whose diagnosis had been made from a defined date. This definition includes all cases with a diagnosis of malignant tumor that, according to the International Classification of Diseases for Oncology,^[@B5]^ present a code of primary malignancy behavior (/ 3). The cases diagnosed from a metastasis, in which the primary tumor was not found, are recorded as "Topography (C80.9) - Unknown primary site"; "Behavior: malignant, primary site."

Frequency analyses of selected variables were performed. For the numerical variables, centralization and dispersion measures and simple frequencies by groups/strata were calculated.

The variables analyzed were age, education level, health coverage, tumor size, lymph node involvement, presence of metastases, clinical and pathologic stage (TNM),^[@B6]^ differentiation degree,^[@B7]^ presence of multiple primary and other tumors, hormone receptors (estrogen receptor \[ER\] and progesterone receptor \[PR\]), and human epidermal growth factor receptor 2 (HER2) overexpression.

An analysis of the time in months between the onset of symptoms and the first appointment at the institution was performed, as well as time between the first medical consultation and the diagnosis, and time between the diagnosis and the beginning of the first treatment (called delays). Because the results showed non-normal distributions, the median and quartiles 1 and 3 were calculated and presented in box plots for better interpretation.

Finally, the survival probability was calculated using the Kaplan-Meier technique. Comparisons between groups were made on the basis of different immunohistochemical profiles, patient age younger or older than 40 years, according to tumor morphology with more frequent malignant behavior, between clinical stages (I and II *v* III and IV), and in the presence or absence of axillar nodes, to evaluate whether the differences between groups were significant using the log-rank test (establishing a significance level of 5%). The STATA SE 12.0 program was used.

Data in RITA are protected under the Law 25.326 and the Decree 1558/2001 of Personal Data Protection.

RESULTS {#s3}
=======

Total usable records in RITA between June 2012 and April 2016 included 27,504 tumors, of which 16,004 were in women. A total of 4,883 patients and 4,950 tumors were identified with breast cancer, representing 18% of all tumors (31% among women). These data were registered by 40 hospitals distributed in 20 of the country's 24 provinces.

The group of patients 55 to 59 years of age had the most cases (14.4%), and 50% of the cases recorded were in patients between 50 and 69 years old. Women younger than 40 years accounted for 8.9% of the cases, and those older than 74 years accounted for 11.9% ([Table 1](#T1){ref-type="table"}). The mean age was 57.6 years; median, 56 years; and mode, 59 years; with an interquartile range of 19 years (quartile 1 = 47, quartile 3 = 66) and a standard deviation of 14.9 years.

###### 

Sociodemographic Characteristics of Patients With Breast Cancer (N = 4,883) From Records in the Institutional Tumor Registry of Argentina, April 2012 to April 2016

![](JGO.2016.009050t1)

Information on education level was obtained in 51.3% of the women ([Table 1](#T1){ref-type="table"}), of whom approximately 60% were enrolled or had completed the primary level, and approximately 30% had completed the secondary level.

At the time of registration, 2,287 women (46.8%) had some type of health coverage ([Table 1](#T1){ref-type="table"}). The rest of the patients only had public health system coverage or their situation was unknown. No patient reported paying for prepaid or private insurance.

Approximately 85% of tumors (n = 4,228) were diagnosed by primary tumor histology, of which 1.8% were described as multiple primaries and 3.4% presented tumors other than breast cancer.

With regard to the clinical stage and TNM stage, 19% were T2, 20% had no palpable lymphadenopathy (N0), and only 4.2% of the cases reported distorted metastases. It can be observed that more of the registered tumors presented clinical stage II (18.6%) than III (16.1%; [Table 2](#T2){ref-type="table"}). Seventy-six percent of the registered breast cancer tumors were reported as ductal carcinomas, and 8% were reported as lobular (with 2.3% as unknown histologic variant).
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Clinical Features of Breast Tumors (N = 4,950) From Records in the Institutional Tumor Registry of Argentina, April 2012 to April 2016
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Information on diagnostic procedure was obtained in 97.7% of cases; 91% of the tumors were diagnosed by histologic analysis, and only in 0.2% was the diagnosis made by death certificate.

A moderate or poor degree of differentiation was found in 60.9% of tumors, predominantly in grade 2 (moderately differentiated; [Table 3](#T3){ref-type="table"}). The presence of hormone receptors was observed in 50.1% of tumors for estrogen and in 45.2% for progesterone. Regarding the molecular profile, the ER-positive/PR-positive/HER2-negative combination was observed in 1,696 tumors (34.3%).

###### 

Frequency of Breast Tumors According to Histologic Characteristics (N = 4,950) From Records in the Institutional Tumor Registry of Argentina, April 2012 to April 2016
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Patients who had received surgical treatment represented 24.5% of the cases (1,215 tumors); 28% of them were classified as stage II, and approximately 15% each as stage I and III ([Table 3](#T3){ref-type="table"}).

Analyzing the diagnostic and therapeutic opportunities ([Fig 1](#F1){ref-type="fig"}), the median delay between the first medical consultation and the diagnosis was 0.9 months (quartile 1 = 0.3 and quartile 3 = 2.2 months; mean, 2.2 months) and between diagnosis and the first treatment was 1.4 months (quartile 1 = 0.3 and quartile 3 = 2.7 months; mean, 2.9 months).

![Diagnostic and treatment delays in patients with breast cancer. Records in the Institutional Tumor Registry of Argentina, April 2012 to April 2016.](JGO.2016.009050f1){#F1}

The overall survival rate at 12 months was 96% (95% CI, 94.8% to 97.0%) and 84.7% at 36 months (95% CI, 80.1% to 88.3%). A significant difference in survival was observed between the immunohistochemical profiles ER positive/PR positive/HER2 negative versus ER negative/PR negative/HER2 positive; *P* = .0179), between patients with axillary-negative versus axillary-positive nodes (*P* = .0054), and between grouped clinical stages (*P* = .0054; [Fig 2](#F2){ref-type="fig"}). No significant differences were found when comparing survival between patients younger or older than 40 years (*P* = .1506). The values are listed in [Table 4](#T4){ref-type="table"}.
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Survival Probability of Patients With Breast Cancer at 12 and 36 Months, According to Several Categories From Records in the Institutional Tumor Registry of Argentina, April 2012 to April 2016
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DISCUSSION {#s4}
==========

The results of this study show that breast tumors were the most frequently registered by the 40 institutions included in RITA during the analyzed period (95% were public health institutions; only five of them had \> 3 years of registry activity, and 62% had begun the registry with cases diagnosed in 2014). This frequency could be a result of the incidence and prevalence of breast cancer in Argentina, similar to what is found in more developed regions. Frequencies similar to or greater than those found in this study have been reported in studies done on the basis of hospital records from the United States;^[@B8]^ Thailand;^[@B9]^ San Luis, Argentina;^[@B10]^ Turkey;^[@B11]^ or Nigeria.^[@B12]^ However, lower values have also been reported,^[@B13]-[@B16]^ probably as a result of differences in socioeconomic contexts and health processes (higher-lower screening, for example).

It was observed that the frequency of patients registered in RITA increased from 45 years of age; in Argentina, the frequency of incident cases increased after 50 years of age, which would explain the occurrence mentioned in the last paragraph. A varied range of ages was observed in the consulted literature. Some hospital records from Asia and Africa^[@B9],[@B12],[@B13],[@B17]-[@B20]^ show higher frequencies in younger patients; records from San Luis (Argentina), the United States, and Spain^[@B8],[@B10],[@B14]^ report older patients. Only Brazil^[@B21]^ reported similar values. This difference indicates that in less-developed regions, breast cancer occurs in younger women, a fact that has already been described in the literature.^[@B22],[@B23]^

Information about education level was stated only in 51% of the recorded patients with breast cancer. More than half of these patients were attending or had completed primary education (90% of cases are reached when adding those with a secondary level). This information is critical because, although the association between high education level (as an approximation of socioeconomic level) and increased risk of breast cancer is well documented,^[@B24],[@B25]^ several articles have also reported on the relationship between higher education level and lower mortality and better survival rates, probably mediated by better knowledge of and attitudes toward pathology.^[@B26]-[@B30]^

Regarding health coverage, excluding the public sector, this study shows that almost half of the patients had some kind of health insurance (National Institute of Social Services for Retirees and Pensioners, health care services managed by trade unions). In some countries, the absence of health insurance is related to worse outcomes.^[@B31]^ In others, public health systems have specific programs to cover women.^[@B32]^ The health system in Argentina is composed of a subsector of universal access (the public sector), the private subsector (prepaid), and health care services managed by trade unions/National Institute of Social Services for Retirees and Pensioners. Paradoxically, Piñeros et al^[@B26]^ point out that in Colombia, there are greater delays in treatment for patients with state-subsidized medical care, even greater than for women without any coverage. Unfortunately, in our study, we could not analyze diagnostic and treatment delays stratified according to health coverage, because of the low percentage of cases with complete data (15%).

An important evaluation measure of diagnostic quality, performed by the health care services, is the method by which the diagnosis was obtained (percentage of cases diagnosed by primary tumor histology).^[@B33]^ In our case, the percentage (91%) is acceptable for the International Agency for Research on Cancer quality criteria (between 60% and 70% of cases).^[@B34]^ Other records also refer to frequencies between 80% and 100%.^[@B12],[@B14],[@B17],[@B21]^

Tumor stage at time of diagnosis contributes to the definition of prognosis and treatment in each case and subsequent evolution. Among patients registered in RITA, one-third acceded to the diagnosis in stages II and III, as in Brazil.^[@B21]^ In the United States and Malaysia-Singapore (middle-to-high and high-income countries), 64% to 66% of women are diagnosed in stages I and II,^[@B8],[@B18]^ and in Indonesia and Thailand, 40% to 45% in stages III and IV.^[@B9],[@B13]^ These findings are consistent with studies that recognize socioeconomic status as a prognostic factor of tumor stage at the time of diagnosis and its evolution.^[@B27]-[@B29],[@B35]-[@B37]^

The most frequent morphologic type of tumor observed in patients included in RITA was ductal carcinoma (histologic differentiation grade 2), coinciding with consulted literature^[@B38]^ and various hospital records (although in different proportions).^[@B8],[@B9],[@B12]-[@B14],[@B16],[@B19]-[@B21]^ Also, regarding the immunohistochemical profile, one-third of patients presented with the ER-positive/PR-positive/HER2-negative subtype, the most frequent and least aggressive.^[@B39],[@B40]^

The greatest delays were observed for initiation of treatment. Fifty percent of women were delayed between 9 and 66 days to access the diagnosis after the first appointment, and between 9 and 81 days to begin the first oncologic treatment after diagnosis. These times are longer compared with those found in other studies and registries,^[@B14],[@B41]^ although lower than those reported in other investigations.^[@B21],[@B26],[@B42]^ Diagnostic delay would generally be related to factors dependent on the health system, such as unequal supply of mammography diagnostic equipment and trained radiologists in breast imaging, as well as cultural issues inherent to patients (eg, education level).^[@B26]^ Delays in treatment may be the result of an increase in the number of women requiring treatment, with a likely decrease in treatment resources,^[@B43]^ as well as in personal situations (education level, socioeconomic level) or affiliation with a health coverage system.^[@B26]^ The correction of these delays is fundamental to attenuating their consequences, especially considering the stage in which patients arrive at the first medical appointment.

In the RITA database, there are few cases that were old enough to reach 5 years of follow up; therefore, survival was described at the first and third years. The first-year survival rate was high (96.0%), similar to that of the United Kingdom, although at 36 months it was 7% lower,^[@B44]^ which would indicate a worse long-term evolution of the disease among our patients, probably as the result of accessibility issues. Without data on 5-year survival, results show an intermediate position among countries such as the United States, the United Kingdom, Canada, Central and Southern Europe, and nations such as Brazil, Eastern Europe, some of Asia, and Oceania.^[@B45],[@B46]^ Comparisons between countries should be interpreted with care, because there are many factors that vary in investigations (period analyzed, included population, quality of data, statistical methodology, and biases because of the presence or absence of screening).^[@B47]^ Another issue is that most of the patients could not reach the 5-year follow-up. Therefore, time analyzed (1 and 3 years) may be insufficient to have a clear idea of the trend in patient survival, which is another reason comparisons should be made with caution.

Regarding survival in different profiles and stages, the differences found between immunohistochemical profiles, presence or absence of axillary nodes, and clinical stages are also observed in the literature consulted.^[@B18],[@B40]^

The percentage of unknown data for certain variables (TNM/stages, hormone receptors, dates for survival) and the geographic coverage of RITA (40 institutions in 20 of the 24 Argentine provinces) are the main limiting factors of the study results, because they could lead to biased results. However, the findings do not contradict those presented in the various studies surveyed, so it could be thought that loss of information would not have much influence on results. The future goal is to improve the quality of the registers and increase the geographical coverage of RITA.

In conclusion, to our knowledge this is the first time in Argentina that systematized data are available on process of care in public health institutions for patients with cancer, which can be used to improve the quality of care. We have observed that RITA reveals important information that allows the identification of subgroups of patients who, as a result of their socio-demographic and clinical characteristics, could present different vulnerabilities in the evolution of their disease. For example, in our view, this is the first time that data on diagnosis and treatment delays and survival of patients with breast cancer from hospital-based registries have been published in Argentina.

However, data collected have high percentages of unknown data for several variables, and too short of follow-up. Therefore, information obtained must be considered as a baseline that needs to be contrasted in the future with higher-quality data and longer observation periods.

Even recognizing the limitations of the registry, we can say that the potential of the information provided by RITA allows us to have approximate national and regional profiles of patients diagnosed with breast cancer, in addition to identifying critical points in the continuum of care, which can be optimized for the best care of patients. There is also the possibility, in the future, to monitor the evolution of survival and opportunities in the different subgroups of identified patients.

We must not forget that RITA is a young registry, and that is one of the main reasons for short follow-up. As a solution to this issue, the authorities of the National Cancer Institute agreed to establish a program of patient navigators^[@B48]^ to ensure the follow-up of patients registered in RITA and to improve their rates of survival. Undoubtedly, RITA presents itself as a significant tool for the management of care organizations, and as a facilitator of control and evaluation actions for the treatment of patients with breast cancer. The improvement of these care processes will surely have a positive impact on the survival observed to date. From this work, we will prioritize actions in RITA that tend to improve the follow-up of patients. This may result in an apparent decrease in the survival of these patients in future analyses as a result of the higher quality of follow-up data and longer observation periods.
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